NCT03664687View on ClinicalTrials.gov

Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)

PHASE4CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

October 31, 2018

Primary Completion Date

April 2, 2020

Study Completion Date

March 28, 2025

Conditions
Early-stage Breast Cancer
Interventions
DRUG

Zoledronate

Administered intravenously (IV)

Trial Locations (6)

L6R 3J7

William Osler Health System, Brampton Civic Hospital, Brampton

L8V 5C2

Juravinski Cancer Centre, Hamilton

K7L 2V7

Kingston Health Sciences Centre, Kingston

L3P 7P3

Markham Stouffville Hospital, Markham

L3Y 2P9

Southlake Regional Health Centre, Newmarket

K1H 8M2

Ottawa Hospital Research Institute, Ottawa

Sponsors
All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER